Severe persistent neurotoxicity associated with CAR T therapy in children

Children who receive CAR T-cell therapy almost universally experience both immune effector cell-associated neurotoxicity syndrome (ICANS) and cytokine release syndrome (CRS) simultaneously, with ICANS usually being reversible. This article provides two atypical cases showing delayed onset of intractable ICANS in children with pre-existing CNS vulnerabilities.